The Pan American Health Organization (PAHO) recommended considering the application of a third dose of the SinoVac and COVID-19 vaccines Sinopharm, authorized by the World Health Organization (WHO), for people with immunosuppression n–moderate or severe.
In the case of SinoVac vaccines y Sinopharm, Jarbas Barbosa, PAHO Deputy Director, recommended that older adults over 80 years old and adults over 60 with some comorbidity, are immunized with a third dose of those specific vaccines.
“There is another recommendation that is specific to the SinoVac and Sinopharm vaccines: reviewing the data, including those produced in Latin America on the use of these two vaccines, it is found that the protection that these vaccines provide for older adults is less than for young adults. So, there is a specific recommendation for these two vaccines, Sinopharm and Sinovac, which in addition to being used for people with immunosuppression, older adults should also be vaccinated with this vaccine ”.
Jarbas Barbosa, PAHO Deputy Director
The PAHO Deputy Director, Jarbas Barbosa, He said that the ideal is for the third dose to be of the same vaccine that was applied; however, if there is no access to the same vaccine, a different one can be applied; WHO authorities have verified that there is no security problem.
“For all vaccines that have emergency use authorization from the WHO, because the evidence group only reviews those vaccines, a third dose should be taken by people who have moderate or severe immunosuppression, they are people, for example, who have active cancer, they are people who received organ transplants ”.
Jarbas Barbosa, PAHO Deputy Director
Sinopharm: authorization in Mexico
Last August, the Federal Commission for the Protection against Sanitary Risks (Cofepris) issued the authorization for emergency use of the Sinopharm vaccine, which, he said, is awarded after a scientific technical review, validating that it complies with the quality, safety and efficacy requirements necessary to be applied.
Through a statement, Cofepris detailed that the vaccine Sinopharm contra COVID-19 had received “A unanimous favorable opinion”:
“As a National Regulatory Authority of reference (ARNr), qualified by the Pan American Health Organization (PAHO), Cofepris decisions are recognized by other countries in the region, therefore not all vaccines approved for emergency use are used in national territory. The Committee for New Molecules (CMN) met on August 23, 2021 on the use of the Sinopharm vaccine, where it received a unanimous favorable opinion from the experts ”.
Cofepris
This authorization to the vacuna Sinopharm adds to those already granted by the World Health Organization (WHO), The pastor May 7, 2021, and 60 health regulatory agencies in the world.
– .
